EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score)
Journal of Clinical Medicine · 01.09.2025 · 14 (17) · 6179
DOI: 10.3390/jcm14176179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.09.2025. Verfasst von Gabriela Marina Andrei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine-Pneumology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the University of Medicine and Pharmacy of Craiova and Saint Nectarie Oncology and Radiotherapy Center, University of Medicine and Pharmacy of Craiova.
Abstract (Originalsprache)
Background/Objectives: Lung cancer remains the leading cause of cancer-related mortality worldwide, with a high proportion of cases diagnosed at advanced stages. Accurate mediastinal staging is essential to guide optimal therapeutic decisions. This study aimed to evaluate the diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and to develop a composite clinical–molecular score (EXPoSURE) for risk stratification.
Methods
A retrospective study was performed that included 131 patients diagnosed with lung cancer between December 2023 and December 2024 at a regional oncology center in Oltenia, Romania. All patients underwent bronchoscopy and EBUS-TBNA using a standardized protocol. Clinical, pathological, and molecular data were collected to assess diagnostic yield, staging performance, and the association with molecular markers. The EXPoSURE score integrated PD-L1, p63, EGFR status, comorbidities, histological type, and TNM stage.
Results
EBUS-TBNA provided a conclusive diagnosis in 91.6% of cases, with a low rebiopsy rate of 8.4% and no requirement for mediastinoscopy. Most patients (68%) were diagnosed at stage IV. PD-L1, p63, and EGFR expression showed no significant correlation with TNM stage, while the EXPoSURE score demonstrated promising stratification capability. Occupational exposure appeared to influence disease severity in some subgroups, although further validation is needed.
Conclusions
EBUS-TBNA is a valuable, safe, and effective approach for minimally invasive diagnosis and mediastinal staging of lung cancer. The proposed EXPoSURE composite score may contribute to a multidimensional risk assessment, supporting more tailored management strategies and warranting prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine-Pneumology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Thoracic Surgery II, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 022328 Bucharest, Romania.
- Department of Medical Informatics and Biostatistics, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Occupational Medicine, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
- Department of Medical Oncology II, "Prof. Dr. Al. Trestioreanu" Institute of Oncology, 022328 Bucharest, Romania.
- Department of Infectious Diseases, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
ORCID-Profile: Virginia Maria Rădulescu, Marius Bunescu, Daniela Luminița Zob, Ramona Cioboată, Mihai Olteanu
Förderung
- the University of Medicine and Pharmacy of Craiova and Saint Nectarie Oncology and Radiotherapy Center
- University of Medicine and Pharmacy of Craiova
Zitieren
APA
Andrei, G. M., Motaș, N., Rădulescu, V. M., Ionovici, N., Bunescu, M., Zob, D. L., Biciușcă, V., Dumitrescu, F., Marcu, E. A., Cioboată, R., & Olteanu, M. (2025). EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score). Journal of Clinical Medicine, 14(17), 6179. https://doi.org/10.3390/jcm14176179
Vancouver
Andrei GM, Motaș N, Rădulescu VM, Ionovici N, Bunescu M, Zob DL, et al. EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score). Journal of Clinical Medicine. 2025;14(17):6179. doi:10.3390/jcm14176179
BibTeX
@article{Andrei2025,
author = {Andrei, Gabriela Marina and Motaș, Natalia and Rădulescu, Virginia Maria and Ionovici, Nina and Bunescu, Marius and Zob, Daniela Luminița and Biciușcă, Viorel and Dumitrescu, Florentina and Marcu, Eugenia Andreea and Cioboată, Ramona and Olteanu, Mihai},
title = {EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score)},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {17},
pages = {6179},
doi = {10.3390/jcm14176179}
}
EUVIMED